ADVBAdvanced Biomed Inc
Is Advanced Biomed struggling financially?
Yes, by its own account. Advanced Biomed told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
15/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $13.4M
- Source filing
- 10-Q 15 May 2026
- Balance sheet
- 31 Mar 2026
Cash runway
-
4months
If the burn speeds up
Empty by Jul 2026
-
7months
If it eases off
Empty by Oct 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$2.6M
÷
Cash burned over the last 12 months
$5.9M
What Advanced Biomed told the SEC
…implemented a 1-for-20 reverse stock split in February 2026 to maintain its listing status and improve its capital structure. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern. The unaudited interim condensed consolidated financial statements for the nine-month period ended March 31, 2026 and 2025 have been prepared on a going concern basis and do not…
Advanced Biomed Inc, Form 10-Q, filed 15 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
Other Biotech/Pharma companies that filed the doubt
- LTRN Lantern Pharma $29.9M
- RNAZ Transcode Therapeutics $48.6M
- SSII SS Innovations International $718.4M
- AIM Aim Immunotech $7.9M
- BGLC BioNexus Gene Lab $4.7M
- PTN Palatin Technologies $17.2M